Select Page

South Delhi Pharma, New Delhi, India

Enbrel (etanercept) Solution for Subcutaneous Use

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

Facts of Enbrel (etanercept)

Enbrel® (etanercept) Solution for Subcutaneous Use
Initial U.S. Approval: 1998
Amgen Inc.
50 mg Single-use Prefilled Syringe
0.98 mL of a 50 mg/mL solution of etanercept
50 mg Single-use Prefilled SureClick® Autoinjector
0.98 mL of a 50 mg/mL solution of etanercept
25 mg Single-use Prefilled Syringe
0.51 mL of a 50 mg/mL solution of etanercept
25 mg Multiple-use Vial
25 mg of etanercept

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Enbrel (etanercept)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Enbrel (etanercept) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

What Enbrel is?

Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of:

  • Rheumatoid Arthritis (RA)
  • Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older
  • Psoriatic Arthritis (PsA)
  • Ankylosing Spondylitis (AS)
  • Plaque Psoriasis (PsO)

What Etanercept is?

Etanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.

In the United States etanercept is indicated for:

  • Moderate to Severe Rheumatoid Arthritis (RA) (Nov 1998)
  • Moderate to Severe Polyarticular Juvenile Rheumatoid Arthritis (May 1999)
  • Psoriatic Arthritis (Jan 2002)
  • Ankylosing Spondylitis (AS) (July 2003)
  • Moderate to Severe Plaque Psoriasis (April 2004)

Reviews

There are no reviews yet.

Be the first to review “Enbrel (etanercept) Solution for Subcutaneous Use”

Your email address will not be published.